Which dyskinesia scale best detects treatment response?

Movement Disorders

Volumn 28, Issue 3, 2013, Pages 341-346

  Goetz, Christopher G ^a   Stebbins, Glenn T ^a   Chung, Kathryn A ^b   Hauser, Robert A ^c   Miyasaki, Janis M ^d   Nicholas, Anthony P ^e   Poewe, Werner ^f   Seppi, Klaus ^f   Rascol, Olivier ^g   Stacy, Mark A ^h   Nutt, John G ^b   Tanner, Caroline M ⁱ   Urkowitz, Alison ^j   Jaglin, Jean A ^a   Ge, Song ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e University of Alabama at Birmingham   (United States)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ PARKINSON S INSTITUTE   (United States)

^j THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

more..

Author keywords

Amantadine; Clinical trials; Clinimetrics; Dyskinesia; Parkinson's disease; Rating scales

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; PLACEBO;

26 ITEM PARKINSON DISEASE DYSKINESIA SCALE; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSKINESIA; HUMAN; LANG FAHN ACTIVITIES OF DAILY LIVING DYSKINESIA RATING SCALE; MAJOR CLINICAL STUDY; MODIFIED ABNORMAL INVOLUNTARY MOVEMENT SCALE; MOVEMENT DISORDER SOCIETY SPONSORED REVISION OF THE UNIFIED PARKINSON DISEASE RATING SCALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RUSH DYSKINESIA RATING SCALE; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; UNIFIED DYSKINESIA RATING SCALE; UNIFIED PARKINSON DISEASE RATING SCALE; UNSPECIFIED SIDE EFFECT;

AGED; AMANTADINE; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84875542011     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25321     Document Type: Article

References (26)

1. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord. 2007;22:1379-1389.
2. Nutt JG. Motor fluctuations and dyskinesias in Parkinson's disease. Parkinsonism Relat Disord. 2001;8:101-108.
3. Colosimo C, Fabbrini G, Beraradelli A. Drug insight: new drugs in development for Parkinson's disease. Nat Clin Pract Neurol. 2006;2:600-610.
4. Bézard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential or new therapies. Nat Rev Neurosci 2001;2:577-588.
5. Rascol O, Arnulf I, Peyro Saint Paul H, et al. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord. 2001;16:708-713.
6. Johnston TH, Brotchie JM. Drugs in development for Parkinson's disease: an update. Curr Opin Investig Drugs. 2006;7:25-32.
7. Durif F, Debilly B, Galitzky M, et al. Clozapine improves dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Neurology. 2004;62:381-388.
8. Goetz CG. Rating scales for dyskinesias in Parkinson's disease. Mov Disord. 1999;14(Suppl 1):48-53.
9. Guy W. AIMS: ECDEU Assessment Manual for Psychopharmacology. Washington, DC: Government Printing Office; 1976.
10. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease inter- and intrarater reliability assessment. Mov Disord. 1994;9:390-394.
11. Parkinson Study Group. Evaluation of dyskinesias in a pilot, randomized placebo-controlled trial of remacemide in advanced Parkinson's disease. Arch Neurol. 2001;58:1660-1668.
12. Guy W. CGI: ECDEU Assessment Manual for Psychopharmacology. Washington, DC: Government Printing Office; 1976.
13. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129-2170.
14. Obeso JA, Grandas F, Fasmonde J, et al. Motor complications associated with chronic levodopa-therapy in Parkinson's disease. Neurology. 1989; 39(Suppl 2):11-19.
15. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). In: Lindvall O, Bjorklund A, Widner H, eds. Intracerebral Transplantation in Movement Disorders. Amsterdam, The Netherlands: Elsevier; 1991:227-241.
16. Defer GL, Widner H, Marie RM, Remy P, Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord. 1999;14:572-584.
17. Hauser RA, Deckers F, Lehert P. Parkinson's disease home diary: further validation and implications for clinical trials. Mov Disord. 2004;19:1409-1413.
18. Katzenschlager R, Schrag A, Evans A, et al. Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure. Neurology. 2007;69:555-563.
19. Goetz CG, Nutt JG, Stebbins GT. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord. 2008;23:2398-2403.
20. Goetz CG, Stebbins GT, Theeuwes A, et al. Temporal stability of the Unified Dyskinesia Rating Scale. Mov Disord. 2011;26:2556-2559.
21. Fox SH, Katzenschlager R, Lim S-Y, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2011;26(Suppl 3):S2-S41.
22. Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004; 75:141-143.
23. Goetz CG, Leurgans S, Raman R, Stebbins GT. Objective changes in motor function during placebo treatment in PD. Neurology. 2000;54:710-714.
24. Goetz CG, Laska E, Hicking C, et al. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord. 2008;23:700-707.
25. Goetz CG, Wuu J, McDermott MP, et al. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008;23:690-699.
26. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erbaum Associates, Inc.; 1988.